STOKE THERAPEUT.DL-,001

Stoke Therapeutics said at the Cantor conference that the Phase III EMPEROR study has prematurely completed recruitment with 162 patients and expects top-line data in Q3 2027. The company plans a staggered regulatory filing in the first half of 2027 and cites open-label extension data over four years showing an ongoing seizure reduction of about 75% in the higher‑dose cohort. Stoke has pro-forma cash of more than $400 million, which it says should fund operations into early 2028, and reports progress in the ADOA program as well as ongoing discussions with the FDA on the statistical analysis of secondary endpoints. » More on de.investing.com

Stoke Therapeutics shares rose in premarket trading after JPMorgan added the stock to its coverage with an "Overweight" rating and a $40 price target. Analyst coverage now totals 14 observers, with no hold or sell recommendations, and the rating aligns with positive coverage from Goldman Sachs, Guggenheim and Wedbush. Stoke also granted incentive stock options to seven new employees and completed recruitment of 162 patients for the Phase 3 EMPEROR study of zorevunersen. The company has funds expected to support operations into early 2028, leaving further upside potential if development progresses. » More on de.investing.com

At a growth conference, Stoke Therapeutics said the Phase III EMPEROR trial has exceeded its target with 162 patients recruited and has seen no study discontinuations to date. The company sees signs of disease‑modifying effects of Zorevunersen in Dravet syndrome in addition to a strong reduction in seizures and plans a rolling regulatory submission starting in Q1 2027, with Phase III data expected in Q3 2027. Stoke also expects 2027 efficacy data for the OSPREY program targeting autosomal‑dominant optic atrophy and emphasized that long‑term data will be central for reimbursement decisions and product labeling. » More on de.investing.com